Robot-assisted laparoscopic debulking surgery for recurrent adult granulosa cell tumors

Autor: Jolijn W. Groeneweg, Joline F. Roze, Wouter B. Veldhuis, Jelle P. Ruurda, Cornelis G. Gerestein, Ronald P. Zweemer

Publikováno v: Gynecologic Oncology Reports, Vol 37, Iss , Pp 100783- (2021)

Despite an often early diagnosis and effective initial surgical management, one third of adult granulosa cell tumors (aGCTs) eventually, and often repeatedly, recurs. Debulking surgery remains the preferred treatment modality for recurrent aGCT, alth

Externí odkaz: https://doaj.org/article/0b466c210e5644feac3ceef0cfa52fd8

[18F]FDG and [18F]FES positron emission tomography for disease monitoring and assessment of anti-hormonal treatment eligibility in granulosa cell tumors of the ovary

Autor: Joline F. Roze, Petronella O. Witteveen, Luc R.C.W. van Lonkhuijzen, Hannah S. van Meurs, Wouter B. Veldhuis, Geertruida N. Jonges, Arthur J. A. T. Braat, Glen R. Monroe, Ronald P. Zweemer, J. W. Groeneweg, Roel J. Bennink

Publikováno v: Oncotarget
Oncotarget, 12(7), 665-673. Impact Journals

Purpose Adult granulosa cell tumors (AGCTs) of the ovary represent a rare malignancy in which timing and choice of treatment is a clinical challenge. This study investigates the value of FDG-PET/CT and FES-PET/CT in monitoring recurrent AGCTs and ass

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::327bde38c6f12d79feda5e096b28a77d
http://europepmc.org/articles/PMC8021033

In vitro systematic drug testing reveals carboplatin, paclitaxel, and alpelisib as a potential novel combination treatment for adult granulosa cell tumors

Autor: S. T. Paijens, Hannah S. van Meurs, Elena Sendino Garví, Geertruida N. Jonges, Ronald P. Zweemer, Gijs van Haaften, J. W. Groeneweg, René H.M. Verheijen, Hans W. Nijman, Karen Duran, Ellen Stelloo, Christianne A.R. Lok, Petronella O. Witteveen, Christina Stangl, Joline F. Roze, Glen R. Monroe, Jurgen M.J. Piek, Ferdinando Sereno, Luc R.C.W. van Lonkhuijzen

Publikováno v: Cancers, 13(3):368, 1-18. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13(3):368, 1-18. MDPI AG
Cancers
Volume 13
Issue 3
Cancers, Vol 13, Iss 368, p 368 (2021)

Adult granulosa cell tumors (AGCTs) arise from the estrogen-producing granulosa cells. Treatment of recurrence remains a clinical challenge, as systemic anti-hormonal treatment or chemotherapy is only effective in selected patients. We established a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c045c9140c78ebabd5b7e05778cde714
https://pure.amc.nl/en/publications/in-vitro-systematic-drug-testing-reveals-carboplatin-paclitaxel-and-alpelisib-as-a-potential-novel-combination-treatment-for-adult-granulosa-cell-tumors(a4eea90d-bfe4-4628-adf9-4696a43c9e61).html

Whole genome sequencing of ovarian granulosa cell tumors reveals tumor heterogeneity and a high-grade TP53-specific subgroup

Autor: Joline F. Roze, Petronella O. Witteveen, Joachim Kutzera, Hans W. Nijman, Jmj Piek, Car Lok, R.H.M. Verheijen, Lrcw van Lonkhuijzen, J. W. Groeneweg, Geertruida N. Jonges, Ellen Stelloo, Ronald P. Zweemer, S. T. Paijens, H. S. van Meurs, Glen R. Monroe, G van Haaften

Adult granulosa cell tumors (AGCTs) harbor a somatic FOXL2 c.402C>G mutation in ∼95% of cases and are mainly surgically removed due to limited systemic treatment effect. In this study, potentially targetable genomic alterations in AGCTs were invest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5f7a88f1ac4b9710042bd0ac77903a3

P174 Generation of organoids from ovarian adult granulosa cell tumours for individualized drug screening

Autor: Ronald P. Zweemer, Ferdinando Sereno, Petronella O. Witteveen, Joline F. Roze, Christina Stangl, J. W. Groeneweg, H. S. van Meurs, S. T. Paijens, Hans W. Nijman, Jmj Piek, Geertruida N. Jonges, L Van Lonkhuijzen, Glen R. Monroe, Christianne A.R. Lok, Ellen Stelloo

Publikováno v: Poster exhibition Day 2.

Introduction/Background Adult granulosa cell tumours (aGCT) constitute a rare subtype of ovarian cancer, with >90% of tumours characterized by the FOXL2 c.402C>G mutation. Recurrences occur in nearly 50% of patients and are associated with a poor pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e85041e78dae85d1fa03da56ddabb6bc
https://doi.org/10.1136/ijgc-2019-esgo.234